Although lapatinib blocks EGFR kinase activity, the contribution of this function to anticancer activity in HER2-positive breast cancer cells appears to be minimal, as loss of HER2 expression reduced lapatinib efficacy, while loss of EGFR expression did not [118]. This evidence concerns the gene EGFR and breast carcinoma.